Dabiran Capsule 150 mg

Dabiran Capsule 150 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Dabiran Capsule 150 mg
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Dabiran Capsule 150 mg
Generic	Dabigatran Etexilate Mesylate
Weight	150 mg
Type	Capsule
Therapeutic Class	Anti-coagulants, Anti-platelet drugs, Fibrinolytics (Thrombolytics)
Manufacturer	Healthcare Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Dabiran Capsule 150 mg is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days ... Read more

Dosage

Dabiran Capsule 150 mg dosage

Reduction in the risk of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation: For patients with CrCl >30 mL/min: 150 mg orally, twice daily For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily Treatment of DVT and PE: For patients with CrCl >30 mL/min: 150 mg orally, twice daily after 5-10 days of parenteral anticoagulation.Reduction in the Risk of Recurrence of DVT and PE:For patients with CrCl >30 mL/min: 150 mg orally,twice daily after previous treatment.Prophylaxis of DVT and PE Following Hip Replacement Surgery: For patients with CrCl >30 mL/min: 110 mg orally first day, then 220 mg once daily. Temporarily discontinue Dabiran Capsule 150 mg before invasive or surgical procedures when possible, then restart promptly.Pediatric Use: Safety and effectiveness of Dabigatran Etexilate in pediatric patients have not been established.Geriatric Use: Of the total number of patients in the RE-LY study, 82% were 65 and over, while 40% were 75 and over. The risk of stroke and bleeding increases with age, but the risk-benefit profile is favorable in all age groups.

Side Effects

Premature discontinuation of Dabigatran Etexilate increases the risk of thrombotic events. Dabigatran Etexilate increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Common side effects of Dabigatran Etexilate include indigestion, upset stomach, or burning, stomach pain. In some people Dabigatran Etexilate can cause symptoms of an allergic reaction.

Precaution

Premature discontinuation of Dabigatran Etexilate increases the risk of thrombotic events. Dabigatran Etexilate increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Epidural or spinal hematomas may occur in patients treated with Dabigatran Etexilate who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. The use of Dabigatran Etexilate is contraindicated in patients with mechanical prosthetic valves. The concomitant use of Dabigatran Etexilate with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided. For patients with triple-positive antiphospholipid syndrome, treatment with Dabigatran Etexilate increases the risk of thrombosis.

Interaction

Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation: The concomitant use of Dabigatran Etexilate with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided.Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism: Avoid use of Dabigatran Etexilate and P-gp inhibitors in patients with CrCl <50 mL/min.Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery: In patients with CrCl ≥50 mL/min who have concomitant administration of P-gp inhibitors such as dronedarone or systemic ketoconazole, it may be helpful to separate the timing of administration of dabigatran and the P-gp inhibitor by several hours. The concomitant use of Dabigatran Etexilate and P-gp inhibitors in patients with CrCl <50 mL/min should be avoided.

Pregnancy & Breastfeeding use

Safety has not been established during pregnancy. Breastfeeding is not recommended during treatment with Dabigatran Etexilate.

Contraindication

Dabigatran Etexilate is contraindicated in patients with active pathological bleeding, patients with history ofserious hypersensitivity reaction to Dabigatran Etexilate and patients with mechanical prosthetic heart valve.

Acute Overdose

Accidental overdose may lead to hemorrhagic complications. In the event of hemorrhagic complications, appropriate clinical support must be initiated, treatment with Dabigatran Etexilate should be discontinued, and the source of bleeding should be investigated. A specific reversal agent (idarucizumab) is available.